Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 6/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964631 | 0.87 | AHR (0.54) | AHRTTR | |
| SCHEMBL2966152 | 0.82 | AHR (0.51) | AHRTTR | |
| SCHEMBL25057530 | 0.81 | NPC1 (0.38) | — | |
| SCHEMBL13201404 | 0.79 | ALDH1A1 (0.43) | AHR | |
| SCHEMBL21191893 | 0.78 | AHR (0.59) | AHRTTRMCL1CA1CA2 | |
| SCHEMBL19502219 | 0.78 | AHR (0.63) | AHRTTRMCL1CA1CA2 | |
| SCHEMBL5992006 | 0.76 | AHR (0.49) | AHRTTRMCL1CA1CA2 | |
| SCHEMBL9779032 | 0.75 | ELANE (0.34) | AHRMCL1 | |
| SCHEMBL21110463 | 0.75 | AHR (0.59) | AHRTTRMCL1 | |
| SCHEMBL21669068 | 0.75 | AHR (0.59) | AHRTTRMCL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| EP-1735300-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7119214-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-12-22 | — | — | US | disclosed |
| WO-2005100345-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | AHR 190/4885TTR 592/4885HTR1A 1/4885 |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | AHR 190/4885TTR 592/4885HTR1A 1/4885 |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | HTR1A, HTR2A, HTR5A | AHR 190/4885TTR 592/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.